These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 30632144)

  • 1. Salvation of the fallen angel: Reactivating mutant p53.
    Li Y; Wang Z; Chen Y; Petersen RB; Zheng L; Huang K
    Br J Pharmacol; 2019 Apr; 176(7):817-831. PubMed ID: 30632144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Awakening the "guardian of genome": reactivation of mutant p53.
    Binayke A; Mishra S; Suman P; Das S; Chander H
    Cancer Chemother Pharmacol; 2019 Jan; 83(1):1-15. PubMed ID: 30324219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological activation of p53 in cancer cells.
    Athar M; Elmets CA; Kopelovich L
    Curr Pharm Des; 2011; 17(6):631-9. PubMed ID: 21391904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structures of oncogenic, suppressor and rescued p53 core-domain variants: mechanisms of mutant p53 rescue.
    Wallentine BD; Wang Y; Tretyachenko-Ladokhina V; Tan M; Senear DF; Luecke H
    Acta Crystallogr D Biol Crystallogr; 2013 Oct; 69(Pt 10):2146-56. PubMed ID: 24100332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent Synthetic Approaches towards Small Molecule Reactivators of p53.
    Silva JL; Lima CGS; Rangel LP; Ferretti GDS; Pauli FP; Ribeiro RCB; da Silva TB; da Silva FC; Ferreira VF
    Biomolecules; 2020 Apr; 10(4):. PubMed ID: 32326087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome.
    Sigal A; Rotter V
    Cancer Res; 2000 Dec; 60(24):6788-93. PubMed ID: 11156366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting mutant p53 for efficient cancer therapy.
    Bykov VJN; Eriksson SE; Bianchi J; Wiman KG
    Nat Rev Cancer; 2018 Feb; 18(2):89-102. PubMed ID: 29242642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Recent advances in mutant p53 and novel personalized strategies for cancer therapy].
    Lu SQ; Jia ST; Luo Y
    Yi Chuan; 2011 Jun; 33(6):539-48. PubMed ID: 21684858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reactivation of mutant p53: a new strategy for cancer therapy.
    Selivanova G; Kawasaki T; Ryabchenko L; Wiman KG
    Semin Cancer Biol; 1998; 8(5):369-78. PubMed ID: 10101802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reactivation of mutant p53 by capsaicin, the major constituent of peppers.
    Garufi A; Pistritto G; Cirone M; D'Orazi G
    J Exp Clin Cancer Res; 2016 Sep; 35(1):136. PubMed ID: 27599722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The gut microbiome switches mutant p53 from tumour-suppressive to oncogenic.
    Kadosh E; Snir-Alkalay I; Venkatachalam A; May S; Lasry A; Elyada E; Zinger A; Shaham M; Vaalani G; Mernberger M; Stiewe T; Pikarsky E; Oren M; Ben-Neriah Y
    Nature; 2020 Oct; 586(7827):133-138. PubMed ID: 32728212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and synthesis of a C7-aryl piperlongumine derivative with potent antimicrotubule and mutant p53-reactivating properties.
    Punganuru SR; Madala HR; Venugopal SN; Samala R; Mikelis C; Srivenugopal KS
    Eur J Med Chem; 2016 Jan; 107():233-44. PubMed ID: 26599530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor suppressor p53 and its gain-of-function mutants in cancer.
    Liu J; Zhang C; Feng Z
    Acta Biochim Biophys Sin (Shanghai); 2014 Mar; 46(3):170-9. PubMed ID: 24374774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutant p53 proteins: between loss and gain of function.
    Strano S; Dell'Orso S; Mongiovi AM; Monti O; Lapi E; Di Agostino S; Fontemaggi G; Blandino G
    Head Neck; 2007 May; 29(5):488-96. PubMed ID: 17123310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. p53 mutant-type in human prostate cancer cells determines the sensitivity to phenethyl isothiocyanate induced growth inhibition.
    Aggarwal M; Saxena R; Asif N; Sinclair E; Tan J; Cruz I; Berry D; Kallakury B; Pham Q; Wang TTY; Chung FL
    J Exp Clin Cancer Res; 2019 Jul; 38(1):307. PubMed ID: 31307507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disarming mutant p53 oncogenic function.
    Girardini JE; Marotta C; Del Sal G
    Pharmacol Res; 2014 Jan; 79():75-87. PubMed ID: 24246451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting mutant p53 for cancer therapy: direct and indirect strategies.
    Hu J; Cao J; Topatana W; Juengpanich S; Li S; Zhang B; Shen J; Cai L; Cai X; Chen M
    J Hematol Oncol; 2021 Sep; 14(1):157. PubMed ID: 34583722
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM.
    Song H; Hollstein M; Xu Y
    Nat Cell Biol; 2007 May; 9(5):573-80. PubMed ID: 17417627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutant p53: an oncogenic transcription factor.
    Strano S; Dell'Orso S; Di Agostino S; Fontemaggi G; Sacchi A; Blandino G
    Oncogene; 2007 Apr; 26(15):2212-9. PubMed ID: 17401430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutant p53 reactivators protect breast cancer cells from ferroptosis.
    Rathnayake DS; Dlamini S; Elkalawozgy K; Tillekeratne LMV; Taylor WR
    Cell Biochem Funct; 2024 Jun; 42(4):e4036. PubMed ID: 38778584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.